受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | MK 4827 tosylate | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C19H20N4O.C7H8O3S |
|||
分子量 | 492.59 | CAS No. | 1038915-73-9 | |
Solubility (25°C)* | 体外 | DMSO | 98 mg/mL (198.94 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Niraparib tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. Niraparib increases formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death. |
---|---|
in vitro | Micromolar concentrations of niraparib radiosensitizes tumor cell lines derived from lung, breast, and prostate cancers independently of their p53 status but not cell lines derived from normal tissues. Niraparib also sensitizes tumor cells to H2O2 and converts H2O2-induced single strand breaks (SSBs) into DSBs during DNA replication[5]. |
in vivo | MK-4827 strongly enhances the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant. MK-4827 reduces PAR levels in tumors by 1 h after administration which persisted for up to 24 h[1]. In vivo treatment with MK-4827 and radiation prolonged survival (p<0.01) compared to single modalities. In vivo superiority of MK-4827 plus radiation is further documented by significant elevations of cleaved caspase-3 and γ-H2AX in tumors from the combination group compared to single modality cohorts[4]. |
細胞アッセイ | 細胞株 | V-C8 cells |
---|---|---|
濃度 | 50 nM | |
反応時間 | 24 h | |
実験の流れ | V-C8 (BRCA2-negative) Chinese hamster cells are treated with the PARP inhibitor MK-4827 for 24 h, washed and incubated in drug-free medium for 5-7 days until colonies formed. |
|
動物実験 | 動物モデル | Female nude mice (Ncr Nu/Nu) |
投薬量 | 25 or 50 mg/kg | |
投与方法 | p.o. |
Data from [Data independently produced by , , Cell Death & Disease, 2017, 8: e3070]
Increased DNA damage in full-grown oocytes is correlated with diminished autophagy activation [ Nat Commun, 2024, 15(1):9463] | PubMed: 39487138 |
Detection of senescence using machine learning algorithms based on nuclear features [ Nat Commun, 2024, 15(1):1041] | PubMed: 38310113 |
Co-Targeting of DTYMK and PARP1 as a Potential Therapeutic Approach in Uveal Melanoma [ Cells, 2024, 13(16)1348] | PubMed: 39195238 |
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors [ Cancer Res, 2023, 83(10):1699-1710] | PubMed: 37129948 |
Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors [ Cancer Res, 2023, 83(16):2750-2762] | PubMed: 37306706 |
OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells [ Front Oncol, 2022, 12:888810] | PubMed: 35619904 |
Novel Paired Normal Prostate and Prostate Cancer Model Cell Systems Derived from African American Patients [ Cancer Res Commun, 2022, 2(12):1617-1625] | PubMed: 36970725 |
Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma [ Mol Cancer, 2021, 20(1):97] | PubMed: 34315482 |
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer [ Nat Cancer, 2021, 2(1):66-82] | PubMed: 33738458 |
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer [ Nat Cancer, 2021, 2(1):66-82] | PubMed: 33738458 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。